1UTG
| REFINEMENT OF THE C2221 CRYSTAL FORM OF OXIDIZED UTEROGLOBIN AT 1.34 ANGSTROMS RESOLUTION | Descriptor: | UTEROGLOBIN | Authors: | Morize, I, Surcouf, E, Vaney, M.C, Buehner, M, Mornon, J.P. | Deposit date: | 1989-04-03 | Release date: | 1989-10-15 | Last modified: | 2017-11-29 | Method: | X-RAY DIFFRACTION (1.34 Å) | Cite: | Refinement of the C222(1) crystal form of oxidized uteroglobin at 1.34 A resolution. J.Mol.Biol., 194, 1987
|
|
4A6L
| beta-tryptase inhibitor | Descriptor: | 1-{3-[1-({5-[(2-fluorophenyl)ethynyl]furan-2-yl}carbonyl)piperidin-4-yl]phenyl}methanamine, TRYPTASE ALPHA/BETA-1 | Authors: | Mathieu, M, Maignan, S. | Deposit date: | 2011-11-04 | Release date: | 2012-01-25 | Last modified: | 2024-05-01 | Method: | X-RAY DIFFRACTION (2.05 Å) | Cite: | Structure-Based Library Design and the Discovery of a Potent and Selective Mast Cell Beta-Tryptase Inhibitor as an Oral Therapeutic Agent. Bioorg.Med.Chem.Lett., 22, 2012
|
|
3VFE
| Virtual Screening and X-Ray Crystallography for Human Kallikrein 6 Inhibitors with an Amidinothiophene P1 Group | Descriptor: | 4-{[(3R)-3-{[(7-methoxynaphthalen-2-yl)sulfonyl](thiophen-3-ylmethyl)amino}-2-oxopyrrolidin-1-yl]methyl}thiophene-2-carboximidamide, Kallikrein-6 | Authors: | Chen, X, Zhang, Y, Xia, T, Wang, R. | Deposit date: | 2012-01-09 | Release date: | 2012-11-21 | Last modified: | 2024-05-01 | Method: | X-RAY DIFFRACTION (1.88 Å) | Cite: | Virtual Screening and X-ray Crystallography for Human Kallikrein 6 Inhibitors with an Amidinothiophene P1 Group. Acs Med.Chem.Lett., 3, 2012
|
|